Stay updated on IMMU-132 Clinical Trial in Epithelial Cancer
Sign up to get notified when there's something new on the IMMU-132 Clinical Trial in Epithelial Cancer page.

Latest updates to the IMMU-132 Clinical Trial in Epithelial Cancer page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe study record for sacituzumab govitecan in adults with epithelial cancer is displayed, including its completed status, eligibility criteria, treatment plan, outcomes, and publications. Study documents and record history are also available.SummaryDifference81%

- Check20 days agoChange DetectedThe ClinicalTrials.gov footer revision label changed from v3.7.2 to v3.8.0, while the study record remains inaccessible.SummaryDifference0.2%

- Check27 days agoChange DetectedA site-wide NIH banner announces updates to terminology for artificial intelligence during a transition. The clinical study record itself remains inaccessible and displays a 403 error.SummaryDifference1%

- Check34 days agoChange DetectedThe footer’s ClinicalTrials.gov revision number changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check41 days agoChange DetectedThe footer revision changed from v3.7.0 to v3.7.1 on the ClinicalTrials.gov error page.SummaryDifference0.2%

- Check48 days agoChange DetectedThe page now shows a 403 Forbidden error in place of the study record for sacituzumab govitecan in adults with epithelial cancer.SummaryDifference22%

Stay in the know with updates to IMMU-132 Clinical Trial in Epithelial Cancer
Enter your email address, and we'll notify you when there's something new on the IMMU-132 Clinical Trial in Epithelial Cancer page.